[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpwIz4MZRfdemYLj00g4jLHCTS4aYu1GKDvUyoKgQG_k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Maastricht Radiation Oncology",[4],106,false,18,3,69246,0,87,[14,17,19,22,25,28,30,32],{"name":15,"count":16},"Lung Cancer",9,{"name":18,"count":16},"Breast Cancer",{"name":20,"count":21},"Non-small Cell Lung Cancer",7,{"name":23,"count":24},"Non Small Cell Lung Cancer",6,{"name":26,"count":27},"Glioblastoma",5,{"name":29,"count":27},"NSCLC",{"name":31,"count":27},"Rectal Cancer",{"name":33,"count":34},"Prostate Cancer",4,[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,91,126,163,189,216,242,268,293,311,329,352,376,400,424,442,466,490],{"intervention":45,"totalTrials":9,"cells":46},"Chloroquine",{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":74,"PHASE3":85,"PHASE4":87,"NA":89},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[51,61],{"nctId":52,"briefTitle":53,"status":54,"phases":55,"primaryCompletion":56,"completion":56,"start":57,"enrollment":27,"conditions":58,"interventions":60},"NCT01575782","Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer","TERMINATED",[38],"2017-07","2014-05",[59],"Small Cell Lung Cancer",[45],{"nctId":62,"briefTitle":63,"status":64,"phases":65,"primaryCompletion":66,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":72},"NCT02378532","The Addition of Chloroquine to Chemoradiation for Glioblastoma","COMPLETED",[38],"2019-01-17","2019-07-30","2016-08",13,[71],"Glioblastoma Multiforme",[45,73],"Temozolomide",{"trials":75,"activeCount":11},[76],{"nctId":77,"briefTitle":78,"status":79,"phases":80,"primaryCompletion":81,"completion":81,"start":81,"enrollment":11,"conditions":82,"interventions":84},"NCT02432417","The Addition of Chloroquine to Chemoradiation for Glioblastoma,","WITHDRAWN",[39],"2023-11-10",[26,83],"Astrocytoma, Grade IV",[45],{"trials":86,"activeCount":11},[],{"trials":88,"activeCount":11},[],{"trials":90,"activeCount":11},[],{"intervention":92,"totalTrials":93,"cells":94},"L19-IL2",2,{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":108,"PHASE3":120,"PHASE4":122,"NA":124},{"trials":96,"activeCount":11},[],{"trials":98,"activeCount":11},[99],{"nctId":100,"briefTitle":101,"status":64,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":8,"conditions":105,"interventions":107},"NCT02086721","Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor",[38],"2017-05","2015-12",[106],"Solid Tumour",[92],{"trials":109,"activeCount":11},[110],{"nctId":111,"briefTitle":112,"status":79,"phases":113,"primaryCompletion":114,"completion":115,"start":104,"enrollment":11,"conditions":116,"interventions":119},"NCT02735850","Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)",[39],"2021-02","2021-06",[117,118],"NSCLC Stage IV","Limited Metastatic Disease",[92],{"trials":121,"activeCount":11},[],{"trials":123,"activeCount":11},[],{"trials":125,"activeCount":11},[],{"intervention":127,"totalTrials":93,"cells":128},"nelfinavir",{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":141,"PHASE3":157,"PHASE4":159,"NA":161},{"trials":130,"activeCount":11},[],{"trials":132,"activeCount":11},[133],{"nctId":134,"briefTitle":135,"status":64,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":24,"conditions":139,"interventions":140},"NCT00694837","Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma",[38],"2013-01","2009-03",[26],[127],{"trials":142,"activeCount":11},[143],{"nctId":144,"briefTitle":145,"status":64,"phases":146,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":156},"NCT00704600","Nelfinavir, a Phase I\u002FPhase II Rectal Cancer Study",[38,39],"2010-09","2013-07","2008-09",15,[152,153,154,155],"Colorectal Cancer","Colorectal Carcinoma","Colorectal Tumors","Neoplasms, Colorectal",[127],{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[],{"trials":162,"activeCount":11},[],{"intervention":164,"totalTrials":165,"cells":166},"Celecoxib",1,{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":183,"PHASE4":185,"NA":187},{"trials":168,"activeCount":11},[],{"trials":170,"activeCount":11},[],{"trials":172,"activeCount":11},[173],{"nctId":174,"briefTitle":175,"status":64,"phases":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT00181532","Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC",[39],"2008-01","2003-05",102,[181],"Non Small Cell Lung Carcinoma",[164],{"trials":184,"activeCount":11},[],{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[],{"intervention":190,"totalTrials":165,"cells":191},"Injection with the hypoxia tracer [18F]HX4,",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":193,"activeCount":11},[],{"trials":195,"activeCount":11},[],{"trials":197,"activeCount":11},[198],{"nctId":199,"briefTitle":200,"status":54,"phases":201,"primaryCompletion":103,"completion":103,"start":202,"enrollment":165,"conditions":203,"interventions":209},"NCT02584400","Tumor Hypoxia With HX4 PET in Several Diseases",[39],"2016-05",[204,205,206,207,208],"Prostatic Neoplasms","Esophageal Neoplasms","Neoplasm Metastases, Brain","Rectal Neoplasms","Brain Neoplasm, Primary",[190],{"trials":211,"activeCount":11},[],{"trials":213,"activeCount":11},[],{"trials":215,"activeCount":11},[],{"intervention":217,"totalTrials":165,"cells":218},"Nitroglycerin patch",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":236,"PHASE4":238,"NA":240},{"trials":220,"activeCount":11},[],{"trials":222,"activeCount":11},[],{"trials":224,"activeCount":11},[225],{"nctId":226,"briefTitle":227,"status":54,"phases":228,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT01210378","Nitroglycerin in Non-small Cell Lung Cancer",[39],"2016-09","2017-03","2011-12",47,[234],"Non Small Cell Lung Cancer (NSCLC)",[217],{"trials":237,"activeCount":11},[],{"trials":239,"activeCount":11},[],{"trials":241,"activeCount":11},[],{"intervention":243,"totalTrials":165,"cells":244},"Rapamycin",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":246,"activeCount":11},[],{"trials":248,"activeCount":11},[],{"trials":250,"activeCount":11},[251],{"nctId":252,"briefTitle":253,"status":64,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT00409994","Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer",[38,39],"2018-08-03","2018-12","2006-09",44,[260],"Rectum Cancer",[243],{"trials":263,"activeCount":11},[],{"trials":265,"activeCount":11},[],{"trials":267,"activeCount":11},[],{"intervention":269,"totalTrials":165,"cells":270},"TH-302",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":285,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":272,"activeCount":11},[],{"trials":274,"activeCount":11},[275],{"nctId":276,"briefTitle":277,"status":79,"phases":278,"primaryCompletion":279,"completion":279,"start":104,"enrollment":11,"conditions":280,"interventions":282},"NCT02598687","Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.",[38],"2016-04",[281],"Esophageal Cancer",[269,283,284],"Carboplatin","Paclitaxel",{"trials":286,"activeCount":11},[],{"trials":288,"activeCount":11},[],{"trials":290,"activeCount":11},[],{"trials":292,"activeCount":11},[],{"intervention":283,"totalTrials":165,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":296,"activeCount":11},[],{"trials":298,"activeCount":11},[299],{"nctId":276,"briefTitle":277,"status":79,"phases":300,"primaryCompletion":279,"completion":279,"start":104,"enrollment":11,"conditions":301,"interventions":302},[38],[281],[269,283,284],{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[],{"trials":308,"activeCount":11},[],{"trials":310,"activeCount":11},[],{"intervention":284,"totalTrials":165,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":314,"activeCount":11},[],{"trials":316,"activeCount":11},[317],{"nctId":276,"briefTitle":277,"status":79,"phases":318,"primaryCompletion":279,"completion":279,"start":104,"enrollment":11,"conditions":319,"interventions":320},[38],[281],[269,283,284],{"trials":322,"activeCount":11},[],{"trials":324,"activeCount":11},[],{"trials":326,"activeCount":11},[],{"trials":328,"activeCount":11},[],{"intervention":330,"totalTrials":165,"cells":331},"Chloroquine, A-CQ 100",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":333,"activeCount":11},[],{"trials":335,"activeCount":11},[336],{"nctId":337,"briefTitle":338,"status":54,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":27,"conditions":342,"interventions":343},"NCT00969306","Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients",[38],"2016-06","2013-09",[59],[330],{"trials":345,"activeCount":11},[],{"trials":347,"activeCount":11},[],{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"intervention":353,"totalTrials":165,"cells":354},"[18F]VM4-037",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":356,"activeCount":11},[],{"trials":358,"activeCount":11},[359],{"nctId":360,"briefTitle":361,"status":79,"phases":362,"primaryCompletion":363,"completion":363,"start":364,"enrollment":11,"conditions":365,"interventions":367},"NCT00935142","Non-invasive Imaging With [18F]VM4-037",[38],"2012-11","2012-01",[366],"Stage 4 Cancer",[353],{"trials":369,"activeCount":11},[],{"trials":371,"activeCount":11},[],{"trials":373,"activeCount":11},[],{"trials":375,"activeCount":11},[],{"intervention":377,"totalTrials":165,"cells":378},"Cetuximab-Zr. 89",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":398},{"trials":380,"activeCount":11},[],{"trials":382,"activeCount":11},[383],{"nctId":384,"briefTitle":385,"status":64,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":16,"conditions":389,"interventions":391},"NCT00691548","Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients",[38],"2015-03","2009-06",[390],"Stage IV Cancer",[377],{"trials":393,"activeCount":11},[],{"trials":395,"activeCount":11},[],{"trials":397,"activeCount":11},[],{"trials":399,"activeCount":11},[],{"intervention":401,"totalTrials":165,"cells":402},"Cetuximab",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":416,"PHASE3":418,"PHASE4":420,"NA":422},{"trials":404,"activeCount":11},[],{"trials":406,"activeCount":11},[407],{"nctId":408,"briefTitle":409,"status":64,"phases":410,"primaryCompletion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT00522886","Phase I Cetuximab and Concurrent Radio-chemotherapy",[38],"2011-07","2007-04",24,[20],[401],{"trials":417,"activeCount":11},[],{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[],{"intervention":73,"totalTrials":165,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":427,"activeCount":11},[],{"trials":429,"activeCount":11},[430],{"nctId":62,"briefTitle":63,"status":64,"phases":431,"primaryCompletion":66,"completion":67,"start":68,"enrollment":69,"conditions":432,"interventions":433},[38],[71],[45,73],{"trials":435,"activeCount":11},[],{"trials":437,"activeCount":11},[],{"trials":439,"activeCount":11},[],{"trials":441,"activeCount":11},[],{"intervention":443,"totalTrials":165,"cells":444},"DTP348",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":446,"activeCount":11},[],{"trials":448,"activeCount":11},[449],{"nctId":450,"briefTitle":451,"status":79,"phases":452,"primaryCompletion":453,"completion":56,"start":230,"enrollment":11,"conditions":454,"interventions":457},"NCT02216669","Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor\u002F Radiosensitizer",[38],"2017-06",[455,456],"Solid Tumors","Head and Neck Neoplasms",[443],{"trials":459,"activeCount":11},[],{"trials":461,"activeCount":11},[],{"trials":463,"activeCount":11},[],{"trials":465,"activeCount":11},[],{"intervention":467,"totalTrials":165,"cells":468},"[18F]HX4",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":479},{"trials":470,"activeCount":11},[],{"trials":472,"activeCount":11},[],{"trials":474,"activeCount":11},[],{"trials":476,"activeCount":11},[],{"trials":478,"activeCount":11},[],{"trials":480,"activeCount":11},[481],{"nctId":482,"briefTitle":483,"status":79,"phases":484,"primaryCompletion":485,"completion":486,"start":148,"enrollment":11,"conditions":487,"interventions":489},"NCT01210131","Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)",[42],"2014-01","2014-08",[488],"Small Cell Lung Cancer (SCLC)",[467],{"intervention":491,"totalTrials":165,"cells":492},"FDG",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":494,"activeCount":11},[],{"trials":496,"activeCount":11},[],{"trials":498,"activeCount":11},[],{"trials":500,"activeCount":11},[],{"trials":502,"activeCount":11},[],{"trials":504,"activeCount":11},[505],{"nctId":506,"briefTitle":507,"status":64,"phases":508,"primaryCompletion":509,"completion":104,"start":510,"enrollment":511,"conditions":512,"interventions":513},"NCT00576563","Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer",[42],"2015-01","2007-03",103,[260],[491]]